Sheffield Sarcoma Research Group - Clinical Trials

Clinical trials for Sarcoma patients at Weston Park Hospital, Sheffield (updated February 2016)

Study
Summary Current Status
Trial set-up Open to recruitment Closed to new recruitment - follow-up continues
Neoadjuvant

STRASS
(EORTC 62092)

A phase III randomised study of pre-operative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma
http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=11721
Euro Ewing
2012
International randomised controlled trial for the treatment of newly diagnosed Ewing’s sarcoma family of tumours
http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=13804
Adjuvant
VORTEX A randomised trial of volume of post-operative radiotherapy given to adult patients with extremity soft tissue sarcoma
http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=1472
GOG-0277 A phase III randomised trial of gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade uterine leiomyosarcoma
https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002852-17/BE
SSGXXII Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence
https://clinicaltrials.gov/ct2/show/NCT02413736
Advanced disease
ANNOUNCE A randomised, double-blind, placebo-controlled, phase 3 trial of doxorubicin plus olaratumab versus doxorubicin plus placebo in patients with advanced or metastatic soft tissue sarcoma
https://clinicaltrials.gov/ct2/show/NCT02451943
Axi-STS A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas
http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-axitinib-advanced-soft-tissue-sarcoma-Axi-STS
rEECur An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
http://www.euroewing.eu/clinical-trials/reecur/index
SCART A phase I/II study of oral MEK inhibitor selumetinib in combination with highly active anti-retrovial therapy for HIV-associated Kaposi’s sarcoma
http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=11876